Sprungnavigation

Keyvisual Pflegbar

Unternavigation

Inhalt

Publikationen

Wiltrud Probst, Heidenheim, und Katja de With, Dresden

Surveillance des Einsatzes von Antiinfektiva im Krankenhaus

Eine Umsetzungshilfe für den Klinikapotheker

Krankenhauspharmazie 2017;38:6–22.

 



Ute Blassmann, Alexandra Assmann, Natallia Rodzkina, Anka C. Röhr, Monika Andraschko, Otto R. Frey

Arzneistoffdosierung bei Patienten unter Nierenersatzverfahren: Ein Vergleich der Standardquellen in der Arzneimittelinformation

Krankenhauspharmazie 2017;38:105



Usman, M., Frey, O. R., & Hempel, G. (2016). Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function. European Journal of Clinical Pharmacology, 1-10.

 



Blassmann, U., Roehr, A. C., Frey, O. R., Vetter-Kerkhoff, C., Thon, N., Hope, W., ... & Huge, V. (2016). Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. Critical Care, 20(1), 343.

 



Brinkmann, A., Röhr, A. C., Köberer, A., Fuchs, T., Preisenberger, J., Krüger, W. A., & Frey, O. R. (2016). Therapeutic drug monitoring and individual dosing of antibiotics during sepsis: Modern or just" trendy"?. Medizinische Klinik, Intensivmedizin und Notfallmedizin.

 



Blassmann, U., Roehr, A. C., Frey, O. R., Koeberer, A., Briegel, J., Huge, V., & Vetter-Kerkhoff, C. (2016). Decreased Linezolid Serum Concentrations in Three Critically Ill Patients: Clinical Case Studies of a Potential Drug Interaction between Linezolid and Rifampicin. Pharmacology, 98(1-2), 51-55.

 



Blassmann, U., Frey, O. R., Röhr, A. C., & Vetter-Kerkhoff, C. (2015). PKP-002 Decreased linezolid serum levels in critically ill patients: clinical case studies of a drug-drug-interaction between linezolid and rifampicin. European Journal of Hospital Pharmacy, 22(Suppl 1), A135-A136.

 



Alobaid, A. S., Brinkmann, A., Frey, O. R., Roehr, A. C., Luque, S., Grau, S., ... & Roberts, J. A. (2015). What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. Journal of Antimicrobial Chemotherapy, dkv412.

 



Anka C Roehr, Otto R Frey, Andreas Köberer, Thomas Fuchs, Sophia Helbig,Alexander Brinkmann, Johan W Mouton

 

Creatinine-clearance as predictor for meropenem clearance

 

ECCMID April 2015, Copenhagen

 



Blassmann U, Frey OR, Röhr AC, Vetter-Kerkhoff C

Linezolid und Rifampicin: subtherapeutische Linezolidkonzentrationen im Serum durch Interaktion?

AM-Info Kongress Januar 2015, Köln



Brinkmann A, Köberer A, Fuchs A, Röhr AC, Preisenberger J, and Frey OR

 

Drug Monitoring bei der Sepsis - modern oder nur "modisch"?

 

Journal für Anästhesie und Intensivbehandlung II. 2015, 14-23. 2015



Brinkmann A, Köberer A, Fuchs Th, et al.

Drug Monitoring bei der Sepsis - modern oder nur "modisch"?

 

In: Kuckelt W, Tonner H, eds. Jahrbuch Intensivmedizin 2015

Lengerich: Pabst Sience Puiblisher, 2015:139-48



Brinkmann A, Röhr AC, Köberer A, Fuchs Th, Preisenberger J, Helbig S,

König C und Frey OR

 

Therapeutisches Drug Monitoring und individualisierte Dosierung von β-Laktam-Antibiotika bei Intensivpatienten

 

Eckart, Forst, Briegel – Intensivmedizin – 66. Erg.-Lfg. 4/15, Kapitel VIII 26 2015



Roehr AC, Frey OR, Koeberer A, Fuchs T, Roberts JA, Brinkmann A

Anti-infective drugs during continuous hemodialysis - using the bench

to learn what to do at the bedside

 

Int J Artif Organs. 2015 Feb 4;38(1):17-22 doi: 10.5301/ijao.5000377

 



Brinkmann A, Köberer A, Fuchs T, Helbig S, Preisenberger J, Röhr AC, Frey OR. Therapeutischen Drug Monitoring (TDM) von β-Laktamen.

In: Infektiologie Update 2014. 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG). Weimar, 16.-18.10.2014. Düsseldorf: German Medical Science GMS Publishing House; 2014. Doc14peg12.

DOI: 10.3205/14peg12, URN: urn:nbn:de:0183-14peg126

Frei verfügbar unter: http://www.egms.de/en/meetings/peg2014/14peg12.shtml



König C, Röhr AC, Frey OR, Fuchs T, KöbererA, Kluge S, Braune S, Nierhaus A, Wichmann D, Langebrake C, Brinkmann A

Adsorptive capacity of a novel cytokine filter for meropenem and ciprofloxacin

ESICM September 2014, Barcelona



Kempf A, Büter I, Röhr A, Frey O

Levetiracetam – Validierung einer HPLC Methode zur Serumspiegelmessung und ihr klinischer Einsatz

Jahrestagung der Deutschen Gesellschaft für Klinische Pharmazie Konstanz, 8./9.11.2014

 

Büter I, Kempf A, Frey O, Röhr A

Stabilität von Ampicillin in Perfusor® Spritzen zur hochdosierten Meningitistherapie

Jahrestagung der Deutschen Gesellschaft für Klinische Pharmazie Konstanz, 8./9.11.2014



Helbig S , Papadimas N, Röhr AC, Köberer A, Frey OR, Fuchs T, Preisenberger J und Brinkmann A.

Piperacillin-Dosisstrategien bei kritisch Kranken im Vergleich

Anästh Intenisvmed 55: S478-S479 (2014)

 

Röhr AC, Frey OR, Köberer A,  Fuchs T, Schmid M und Brinkmann A.

Kein Einfluss von Erythromycin auf die Pharmakokinetik von Linezolid

Anästh Intenisvmed 55: S491(2014)



Therapeutisches Drug Monitoring von Ceftriaxon

Pauls C., Röhr A.C., Köberer A., Frey O.R. PZ Prisma 21:177-181 (2014)



Das praktische Jahr in der pharmazeutischen Ausbildung

Reiner D und  Röhr A. Krankenhauspharmazie 35:338-340 (2014)



Stabilität von Ampicillin und Sulbactam in Perfusor-Spritzen

Blassmann U, Vetter-Kerkhoff C, Röhr A und Frey O. Krankenhauspharmazie 35:177-178(2014)



Effektive und ökonomische Antibiotikatherapie

Frey OR und Brinkmann A. Management & Krankenhaus 3/2014, S. 1



Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

The Lancet Infectious Diseases, Volume 14, Issue 6, Pages 498 - 509, June 2014

doi:10.1016/S1473-3099(14)70036-2

Prof Jason A Roberts PhD a b , Mohd H Abdul-Aziz BPharm a, Prof Jeffrey Lipman MD a b, Prof Johan W Mouton PhD c, Prof Alexander A Vinks PhD d, Dr Timothy W Felton MBBS e, Prof William W Hope PhD f, Dr Andras Farkas PharmD g, Michael N Neely MD h, Dr Jerome J Schentag PharmD i, Prof George Drusano MD j, Dr Otto R Frey PhD k, Dr Ursula Theuretzbacher PhD l, Dr Joseph L Kuti PharmD m, on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases



An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units.

Wong, G., Brinkman, A., Benefield, R. J., Carlier, M., De Waele, J. J., El Helali, N., ... & Roberts, J. A.

Journal of Antimicrobial Chemotherapy 2014;69:1416-1423, dkt523



Can we successfully predict dialysate loss of antimicrobial agents in continuous venovenous haemodialysis?

Anka Roehr

Heidenheim, Germany

Roehr, A.C.(1)*; Frey, O.R.(1); Freyberg von, P.(2); Helbig, S.(1); Traeger, K.(3);

https://www.escmid.org/escmid_library/online_lecture_library/material/?mid=14880

 

No effects on linezolid pharmacokinetics by erythromycin

Anka Roehr

Heidenheim, Germany

Roehr, A.C.(1)*; Frey, O.R.(1); Köberer, A.(2); Fuchs, T.(2); Schmid, M.(1); Brinkmann, A.(2);

https://www.escmid.org/escmid_library/online_lecture_library/material/?mid=14881

 

Complete in vitro adsorption of anti-infective drugs to an extracorporeal cytokine filter

Christina König

Hamburg, Germany

König, C.(1)*; Röhr, A.C.(2); Frey, O.R.(2); Köberer, A.(3); Nierhaus, A.(4); Langebrake, C.(1); Kluge, S.(4); Brinkmann, A.(3);

https://www.escmid.org/escmid_library/online_lecture_library/material/?mid=13858

 

Augmented clearance of linezolid in the critically ill: cause for concern?

Otto Roman Frey

Heidenheim, Germany

Frey, O.R.(1)*; Fuchs, T.(2); Helbig, S.(1); Köberer, A.(2); Röhr, A.C.(1); Brinkmann, A.(2);

https://www.escmid.org/escmid_library/online_lecture_library/material/?mid=13879

 



Brinkmann A., Köberer A., Fuchs T., Röhr A.C., Preisenberger J. und Frey O.R.  Drug Monitoring bei der Sepsis – modern oder nur modisch?

Journal für Anästhesie und Intensivbehandlung 2/2014: 9-14 (2014)



S. Helbig1, A.C. Röhr1, J.A. Preisenberger1, O.R. Frey1, A. Brinkmann2, K. Gerlach3, M.C. Bührle3, G. Geldner3

Potentielle Adsorption von Antiinfektiva und Antikonvulsiva an Schlauch- und Filtermaterialien unter extrakorporaler Membranoxygenierung (ECMO)

1Klinikum Heidenheim, Apotheke, Heidenheim, Germany, 2Klinikum Heidenheim, Anästhesiologie und Intensivmedizin, Heidenheim, Germany

3Klinikum Ludwigsburg, Anästhesiologie und Intensivmedizin, Ludwigsburg, Germany

Freie Vorträge 4. Preis

DIVI Leipzig Dezember 2013

 



Probst W. Antibiotika-Führerschein - Klinikinterne Fortbildung im Sinne von Antibiotic Stewardship. Krankenhauspharmazie 34:478-482 (2013)



Frey OR und Röhr AC. Dosierung bei kontinuierlicher Nierenersatztherapie. Pharm Ztg 158(41): 24-26 (2013)

 

Frey OR und Röhr AC. Dosierung bei intermittiernder Hämodialyse. Pharm Ztg 158(40): 24-28 (2013)



Röhr AC, Frey OR, Köberer A, Fuchst T, Preisenberger J, König C, Helbig S und Brinkmann A. In vitro Dialysierbarkeit antiinfektiver Arzneistoffe unter kontinuierlicher Hämodialyse. Anästh Intenisvmed 54: S498 (2013)

2. Posterpreis, beim 15. Hauptstadtkongresses für Anästhesiologie und Intensivtherapie (HAI) der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI) 2013 ICC Berlin.

 

Preisenberger J, Röhr AC, Frey OR, Köberer A, Fuchst T, König C, Helbig S und Brinkmann A. In vitro Dialysierbarkeit antiinfektiver Arzneistoffe unter kontinuierlicher Hämofiltration. Anästh Intenisvmed 54: S497 (2013)

 

König C, Röhr AC, Frey OR, Preisenberger J, Helbig S, Baehr M, Langebrake C und Brinkmann A. In vitro Dialysierbarkeit antiinfektiver Arzneistoffe unter sustained low-efficiency dialysis. Anästh Intenisvmed 54: S492 (2013)

 

Helbig S , Röhr AC, Frey OR, Köberer A, Preisenberger J, König C und Brinkmann A. In vitro Dialysierbarkeit antiinfektiver Arzneistoffe unter intermittierender Hämodialyse. Anästh Intenisvmed 54: S489 (2013)

 

Köberer A, Frey OR, Papadimas N, Röhr AC, Fuchst T und Brinkmann A. Kontinuierliche Applikation und therapeutisches Drug-Monitoring von Piperacillin bei kritisch kranken Patienten. Anästh Intenisvmed 54: S474 (2013)



Frey OR, Köberer A, Röhr AC, Presienberger J, Brinkmann A. Optimale Dosierung und Applikation von Antiinfektiva. INTENSIV (2013) 21 (5): 264-267



Frey OR, Köberer A, Röhr AC, Fuchs T, Brinkmann A. Therapeutisches Drug Monitoring (TDM) von Antiinfektiva bei kritisch Kranken. INTENSIV-News (2013) 17 (4): 16-18



Preisenberger JA, Köberer A, Frey OR, Fuchs T, Helbig S, Röhr AC, Brinkmann A. Comparison of different equations to predict meropenem clearance from serum creatinine concentration in critically ill patients. Infection (2013) 41 (Suppl 1): S55



Röhr AC , Frey OR , Köberer A , Fuchs T, Helbig S , König C, Preisenberger JA , Brinkmann A. Comparison of antibiotic clearance in different renal replacement therapies. Infection (2013) 41 (Suppl 1): S55



Köberer A, Frey OR, Papadimas N, Fuchs T, Röhr A, Brinkmann A. Continuous infusion of piperacillin and therapeutic drug monitoring for treatment of critically ill patients. Infection (2013) 41 (Suppl 1): S54



Köberer A, Frey OR, Fuchs T, Röhr A, Brinkmann A. Continuous infusion of meropenem and therapeutic drug monitoring for treatment of critically ill patients. Infection (2013) 41 (Suppl 1): S53-54

 



Kontinuierliche Applikation und therapeutisches Drug-Monitoring von Piperacillin bei kritisch kranken Patienten


Andreas Köberer, Otto Roman Frey, Nikolaos Papadimas, Anka Röhr, Thomas Fuchs, Alexander Brinkmann (Heidenheim, DE)



Dialysability of antiinfective drugs: an in vitro model with continuous haemodialysis

A.C. Röhr, O.R. Frey, A. Köberer, T. Fuchs, J.A. Preisenberger, S.L. Helbig, A. Brinkmann (Heidenheim, DE)



Comparison of Meropenem dosing regimens in critically ill patients

O.R. Frey, A. Köberer, T. Fuchs, A.C. Röhr, A. Brinkmann

(Heidenheim, DE)



Preisenberger JA, Frey OR Konsil unter Berücksichtigung der aktuellen Nierenfunktion

 

Frey OR 

Vancomycin - Neue Dosisempfehlungen bei intermittierender Hämodialyse. Krankenhauspharmazie 34(1):27-28 (2013)

 



Frey OR, Preisenberger J, Fuchst T, Köberer A, Röhr AC und Brinkmann A. Software CADDy - Arzneimitteldosierung bei akuter und chronischer Niereninsuffizienz, kontinuierlichen Nierenersatzverfahren und intermittierender Dialyse.

 



Frey OR, Brinkmann A, Fuchs T, Köberer A und Preisenberger J. Rationale Dosierung von Arzneimitteln bei Patienten mit Nierenersatzverfahren - (k)ein Problem? Anästh Intenisvmed 53: S525 (2012)

 



Köberer A, Frey OR, Fuchst T, Röhr AC und Brinkmann A. Kontinuierliche Applikation und therapeutisches Drug-Monitoring von Meropenem bei Intensivpatienten Anästh Intenisvmed 53: S511-512 (2012)

 

1. Preis freie Vorträge, beim 14. Hauptstadtkongresses für Anästhesiologie und Intensivtherapie (HAI) der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI) 2012 ICC Berlin.

 



Röhr AC, Frey OR, Köberer A, Fuchst T und Brinkmann A. Dialysierbarkeit von Anidulafungin und Fluconazol Anästh Intenisvmed 53: S537 (2012)

 

1. Posterpreis, beim 14. Hauptstadtkongresses für Anästhesiologie und Intensivtherapie (HAI) der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI) 2012 ICC Berlin.



Frey OR und Sawazki J. Effektivere Arzneimitteltherapie durch therapeutisches Drug-Monitoring, Krankenhauspharmazie 32(5):299-300 (2011)

 

Preisenberger JA und Frey OR. Das Arzneimittel-Konsil unter Berücksichtigung der Nierenfunktion – lohnt sich der Aufwand? Krankenhauspharmazie 32(5):326-327 (2011) 

Download

 

Stumpf AD, Frey OR und Köberer A. Stabilität und Kompatibilität von Meropenem und Vancomycin in Perfusorspritzen. Krankenhauspharmazie 32(5):335 (2011)

Download

 

Frey OR,  Bias M und Köberer A, Therapeutisches Drug Monitoring von Meronem in der klinischen Praxis, Krankenhauspharmazie, 31(12), 525-531(2010)

 

Bias M, Frey OR,  und Köberer A, HPLC-Methode zur quantitativen Bestimmung von Meronem im Serum, Krankenhauspharmazie, 31(11), 482-486(2010)

 

Probst W, Frey OR, Klinische Pharmakokinetik, Pharmakokinetische Besonderheiten bei Senioren, Dosisindividualisierung bei Organinsuffizienzen und Therapeutisches Drug Monitoring in: Repetitorium klinische Pharmazie: Arbeitsbuch für Prüfung und Praxis , Petra Högger/Egid Strehl (Hrsg.),  Govi-Verlag Eschborn, 2. überarbeitete Auflage 2010

 

Fellhauer M, Frey OR, Schuhmacher C und Probst W, Top-Literatur für die Arzneimittelinformation, Krankenhauspharmazie, 31(9), 406-410 (2010)

Download

 

Frey OR,  Maximaldosis von Simvastatin zur Minimierung des Myopathierisikos? Medizinische Monatsschrift für Pharmazeuten, 33(9), 354-355 (2010)

 

Frey OR,  Operationen bei Corticoid-Dauertherapie: Glucocorticoid absetzen, beibehalten oder zusätzliche Gabe von Hydrocortison? Medizinische Monatsschrift für Pharmazeuten, 33(5), 183-184 (2010)

 

Frey OR und Probst W, Unterstützung durch die elektronische Arzneimittelliste AMeLI 3.0 in der Umstellung der Hausmedikation auf Präparate der Arzneimittelliste, Krankenhauspharmazie, 31(5), 197 (2010)

 

Frey OR,  Ist Stillen unter Lamotrigin-Therapie der Mutter möglich? Medizinische Monatsschrift für Pharmazeuten, 33(3), 101 (2010)

 

Frey OR und Wollenberg E,  Protonenpumpenhemmer und Calciumresorption? Medizinische Monatsschrift für Pharmazeuten, 33(1), 25 (2010)

 

Biegert C, Frey OR, Probst W und  Hetzel J, Notwendigkeit der Optimierung einer Arzneimitteltherapie bei Patienten mit Asthma bronchiale und COPD, Krankenhauspharmazie, 30(6), 291-97 (2009)

 

 

Frey OR, Therapeutisches Drug-Monitoring, Krankenhauspharmazie, 30(5), 222-24 (2009)

Download

 

Biegert C, Patientenschulungen am Beispiel inhalativer Arzneiformen, Krankenhauspharmazie, 30(5), 245-47 (2009)

Download

 

Probst W, Pharmazeutische Betreuung von Patienten bei Verabreichung von Arzneimittel über Ernährungssonde, Krankenhauspharmazie, 30(5), 248-50 (2009)

Download

 

Grieb W, Erarbeitung einer regionalen Arzneimittelliste Antikonvulsiva, Krankenhauspharmazie, 30(5), 251-52 (2009)  

 

Probst W, Arzneimittelgabe über Ernährungssonde – Mörsern erlaubt? In: Dörr B, Lerneinheit Nahrungs- und Flüssigkeitsversorgung (Teil 1) – Enteral ernähren, CNE.fortbildung – Certified Nursing Education 2, März 2009

Download

 

 

 

Fellhauer M, Frey OR, Probst W und  Schuhmacher C, Top-Literatur für die Arzneimittelinformation, Krankenhauspharmazie, 30(1), 19-20 (2009)

 

 

 

Probst W, Frey OR, Klinische Pharmakokinetik, Pharmakokinetische Besonderheiten bei Senioren, Dosisindividualisierung bei Organinsuffizienzen und Therapeutisches Drug Monitoring in: Repetitorium klinische Pharmazie: Arbeitsbuch für Prüfung und Praxis , Petra Högger/Egid Strehl (Hrsg.),  Govi-Verlag Eschborn, 1. Aufl. 2007.

 

 

Wagner R, Frey OR, Arzneimittel in der Pädiatrie, in: Klinische Pharmazie / Hrsg. Christian Franken, Michael Hartmann, Urban & Vogel München, 1. Aufl. 2006 

 

 

Rikanovic C, Frey OR, Von der Arzneimittelliste zur klinikinternen Arzneimittel-Datenbank – Entwicklung von AMeLI 2.0, Krankenhauspharmazie 2007; 28(1): 1-4

 

 

Probst W, Sondengängigkeit von Ergenyl Chronosphere Retardgranulat,

Krankenhauspharmazie 2006; 27(10): 436-438.

Abstract: The administration of Ergenyl Chronosphere granules via different feeding tubes was analysed. These granules are a new sustained-release formulation of valproate marked in Germany since October 2005. They pass the nasoenteric tubes >=10 CH and the percutaneous tubes (PEG) >=9 CH gauge in size without problems. The new formulation seems to be suitable for administration via usual feeding tubes.

 

 

Vasel-Biergans A unter Mitarbeit von Probst W, Wundauflagen für die Kitteltasche, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 2. Auflage 2006

 

 

Wagner R, Frey OR, Arzneimittelanwendung bei Kindern und Jugendlichen, Therapeutische Umschau 2006; 63 (6): 411-418

Abstract: In many cases, pharmaceutical manufacturers do not embark on lenghty licencing procedures for pediatric medications. Therefore, formulations and dosages suitable for children are often not available, and even medications that have been approved for pediatric use sometimes lack the information and tools required for correct usage. Therefore, choosing a suitable medication that allows for individual dosing, taking into account physiological peculiarities, providing appropriate tools and comprehensive information/or parents and/or nursing staff is vital to the success of drug treatments in pediatric patients.

 

 

Bruhn C, Frey OR, Wagner R, Das Kind in der Apotheke, Deutscher Apotheker Verlag Stuttgart 2006

 

 

Frey OR, Probst W, Theophylline, in: Clinical Pharmacokinetics, edited by Dhillon S, Kostrzewski A, Pharmaceutical Press London 2006, p. 149-168 

 

 

Probst W, Arzneimitteltherapie bei Patienten mit Ernährungssonde – Beitrag des Apothekers

(Drugs and enteral feeding tubes: Aspects of pharmaceutical care), Medizinische Monatsschrift für Pharmazeuten. 2005; 28(11): 376-388

 

  

Kern WV,  De With K, Steib-Bauert M, Fellhauer M, Plangger A, Probst W, Amann S, Schmid N, Hofmann S, Antibiotic use in non-university regional acute care general hospitals in southwestern Germany, 2001-2002., Infection 2005; 33(5-6): 333-339

Background: A previous study from Germany showed high antibiotic use in university hospitals, particularly in intensive care units (ICU) and hematology-oncology services, but there has been no information about recent antibiotic use in non-university hospitals. In the present study, we collected data from 40 non-university regional general hospitals located in the southwestern part of the country, and analyzed use density in the medical and surgical services of these hospitals. Materials and Methods: Hospital pharmacy records for the calendar years 2001 and 2002 were evaluated. The number of defined daily doses (DDD, definition according to the WHO/ATC 2001 index) and prescribed daily doses (PDD) per 100 patient days (DDD/100 or PDD/100, respectively) were calculated to compare antibiotic use densities in medical and surgical services. Data for surgery included various subspecialties and gynecology. Results: Antibiotic use in the participating hospitals increased minimally between 2001 and 2002 both in medicine as well as in surgery. Use density in internal medicine (ICU areas excluded) in the year 2002 ranged between 13.5 and 93.7 DDD/100 with a weighted mean of 49.9 DDD/100 (corresponding to 28.6 PDD/100, respectively). Values for surgery were lower with a weighted mean of 43.4 DDD/100 (corresponding to 26.1 PDD/100, range, 10 to 65.4 DDD/100), respectively. Hospital size was not a strong predictor of use density, while large differences were observed between intensive care areas and normal wards. Mean use densities in intensive care areas in 2002 were 105.6 DDD/100 (or 49.7 PDD/100) in medical intensive care units, 116.9 DDD/100 (or 61.2 PDD/100) in surgical intensive care units, and 112.7 DDD/100 (or 66.7 PDD/100) in mixed, interdisciplinary intensive care units. Betalactams made up > 50% of all PDDs, while fluoroquinolones were the second most frequently prescribed drugs (15% of all PDDs). Fluoroquinolones were usually given orally. Overall glycopeptide and aminoglycoside use was < 1 PDD/100. Conclusion: This recent data from a large regional non-university acute care hospital sample confirms that hospital antibiotic use density largely depends on patient care areas and less on hospital size. Surprisingly low use was observed for glycopeptides and aminoglycosides. The data may be useful, as a benchmark for further pharmacoepidemiologic evaluation and focused drug use control interventions.

 

 

Probst W, Itraconazole: Monographie der Arbeitsgruppe antiinfektiöse Therapie des Ausschusses Klinische Pharmazie der ADKA (Monography of the working group antiinfectious therapy of the ADKA committee for clinical pharmacy) Krankenhauspharmazie 2005; 26 (6): 222-223

 

 

Vasel-Biergans A, Probst W, Wundversorgung für die Pflege – Ein Praxisbuch, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart 2005

 

 

Kammerer B, Kahlich R, Biegert C, Gleiter CH, Heide L, HPLC-MS/MS analysis of willow bark extracts contained in pharmaceutical preparations. Phytochemical Analysis 2005, 16(6):470-8

Abstract: Preparations containing willow bark extract are popular herbal remedies, but they are mostly standardised with respect to only one compound (usually salicin). RP-HPLC using a C18-column eluted with water:methanol:tetrahydrofuran and coupled to electrospray triple-quadrupole MS and MS/MS was used for the characterisation of dried extracts of Salix spp. and for the identification of their constituents. Comparison with reference substances led to the identification of 13 compounds (saligenin, salicylic acid, salicin, isosalicin, picein, salidroside, triandrin, salicoylsalicin, salicortin, isosalipurposide, salipurposide, naringenin-7-O-glucoside and tremulacin). Two pharmaceutical preparations containing willow bark extract, used in clinical trials and labelled Salix daphnoides and S. purpurea x daphnoides extracts, were compared using the described method and exhibited several clear differences, the most prominent of which was the possible presence of picein in the former preparation. The described method may be utilised for the characterisation of herbal medicines in order to ensure comparability of medication in further clinical trials.

 

 

Probst W, Arzneimitteltherapie bei Patienten mit Ernährungssonde -  3 Fallbeispiele (Drug therapy in patients with enteral feeding tubes - 3 Case reports), Aktuelle Ernährungsmedizin. 2004; 29(6): 338-340

Abstract: In patients receiving enteral nutrition numerous pharmacotherapeutic aspects have to be considered concerning the choice and safe administration of drugs. Three case reports are presented to point out the contribution the clinical pharmacist can offer. Modified-release products and drugs with a narrow therapeutic range are critical drugs as exemplified by phenytoin which absorption decreases dramatically when given concomitantly with enteral nutrition. The clinical pharmacist can have a positive impact in guiding medical staff and patients. Written recommendations should accompany every patient with a enteral feeding tube. The recommendations should include relevant information for each drug as well as general advice for the appropriate method of administration.

 

 

Probst W, Vasel-Biergans A, Wundmanagement – Ein illustrierter Leitfaden für Ärzte und Apotheker, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart 2004

 

 

Frey OR, Grieb W, Hald M, Probst W, Die elektronische Arzneimittelliste im Intranet – Ein Beitrag zur klinisch-pharmazeutischen Betreuung, (The electronic drug list on intranet: A contribution to clinical-pharmaceutical care), Krankenhauspharmazie 2004, 25(9): 389-393

 

 

Biegert C, Wagner I, Lüdtke R, Kötter I, Lohmüller C, Günaydin I, Taxis K, Heide L, Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. Journal of Rheumatology 2004, 31(11): 2121-30

Abstract: OBJECTIVE: To investigate the efficacy and safety of a standardized willow bark extract in patients with osteoarthritis (OA) and rheumatoid arthritis (RA). METHODS: We studied 127 outpatients with hip or knee OA and a WOMAC pain score of at least 30 mm and 26 outpatients with active RA in 2 randomized, controlled, double-blind trials with followup for 6 weeks. OA trial: Patients were randomized to receive willow bark extract, corresponding to 240 mg of salicin/day, diclofenac 100 mg/day, or placebo (n = 43, 43, and 41, respectively). Main outcome measure was the pain subscore of the WOMAC OA Index. RA trial: Patients were randomized to receive willow bark extract, corresponding to 240 mg salicin/day (n = 13) or placebo (n = 13). Main outcome measure was the patient's assessment of pain rated on a 100 mm visual analog scale (VAS). RESULTS: OA trial: WOMAC pain scores decreased by 8 mm (17%) in the willow bark group and by 23 mm (47%) in the diclofenac group, compared with 5 mm (10%) in the placebo group. The difference between willow bark extract and placebo was not statistically significant (-2.8 mm; 95% CI -12.1 to 6.4 mm; p = 0.55, ANCOVA), but the difference between diclofenac and placebo was highly significant (-18.0 mm; 95% CI -27.2 to -8.8 mm; p = 0.0002, ANCOVA). RA trial: The mean reduction of pain on the VAS was -8 mm (15%) in the willow bark group compared with -2 mm (4%) in the placebo group. The difference was not statistically significant (estimated difference -0.8 mm; 95% CI -20.9 to 19.3 mm; p = 0.93, ANCOVA). CONCLUSION: The OA study suggested that the willow bark extract showed no relevant efficacy in patients with OA. Similarly, the RA trial did not indicate efficacy of this extract in patients with RA.

 

 

Biegert C, Heide L, Evidenzbasierte Phytotherapie bei Schmerzen? Ein aktueller Überblick (Evidence-based phytotherapy in the treatment of pain? – An overview of current knowledge), Zeitschrift für Phytotherapie 2004, 25 (2): 97-106

Summary

Herbal medicine is very popular in the population. Besides the common use of herbal

medicines in gastrointestinal disorders, nervous disorders and common colds, there is a

growing number of patients who seek herbal medicines for the treatment of rheumatic

diseases and pain. This review focuses on the current knowledge on preparations of

peppermint, different capsicum species, devil’s claw, willow bark, and stinging nettle. The

scientific evidence of their efficacy, proven by randomized controlled trials, is discussed. For

a thorough evidence-based evaluation of herbal analgesics, published data are not sufficient at present, with the exception of capsaicin preparations. Further clinical trials on the efficacy of herbal medicines in these indications are required.

 

Sturm C, Siffermann A, Frey OR, Transdermale therapeutische Systeme in der Schmerztherapie – Praktische Hinweise zur Anwendung, Krankenhauspharmazie 2003; 24: 7-14

 

 

Wagner I, Biegert C, Heide L, Phytoanalgetika. Aktuelle Forschungsergebnisse zur Weidenrinde, Pharmazeutische Zeitung 2003; 148:1153-1164 

 

 

Frey OR, Orale Sauerstofftherapie (Oral oxygen therapy), Internistische Praxis 2002; 42(4): 856-857

 

 

Frey OR, Maier L, Pecar A, Predel B, Wagner R, PÄD-I.V. – Sichere Anwendung von intravenösen Arzneimitteln bei Kindern, 2. Auflage 2002 

 

 

Burmeister HO, Frey OR, Probst W, Immel-Sehr A, Rechnen in der Pharmazie, GOVI-Verlag Eschborn 2002

 

 

Frey OR, Benefits and risks of colloidal silver. Internistische Praxis 2002; 42(1): 159-160

 

 

Frey OR, Reisekrank – was kann man tun? (How to treat travel sicknesses?),

Medizinische Monatsschrift für Pharmazeuten 2001; 25(7): 244-245

 

 

Frey OR, Lactosehaltige Arzneimittel bei Lactoseintoleranz? (Lactose-containing drugs in lactose intolerance?), Medizinische Monatsschrift für Pharmazeuten 2002; 25(1): 22

  

 

Schmid B, Biegert C, Kötter I, Heide L, Pharmakokinetik von Salicin nach oraler Gabe eines standardisierten Weidenrindenextraktes, in: Phytopharmaka VII . Forschung und klinische Anwendung, 2002, Hrsg.: Schulz V, Rietbrock N, Roots I, Loew D, Steinkopff Verlag, Darmstadt, S. 93-100

 

 

Frey OR, Kontrazeptiva für Epileptikerinnen (Hormonal contraceptives for women with epilepsy?), Medizinische Monatsschrift für Pharmazeuten 2001; 24(11): 379

 

 

Frey OR, Antiepileptika absetzen? Medizinische Monatsschrift für Pharmazeuten 2001; 24(8): 266

 

 

Frey OR, Kolloidales Silber bei Infektionen? (Colloidal silver for therapy of infection?),

Medizinische Monatsschrift für Pharmazeuten 2001; 24(5): 165

 

 

Frey OR, Sodbrennen in der Schwangerschaft (Heartburn during pregnancy),

Medizinische Monatsschrift für Pharmazeuten 2001; 24(4): 129

 

 

Frey OR, Magnesium und Sport? (Magnesium and sport?), Medizinische Monatsschrift für Pharmazeuten 2001; 24(2): 61

 

 

Frey OR, Arzneimittel zur Raucherentwöhnung? (Drugs for smoking cessation?),

Medizinische Monatsschrift für Pharmazeuten 2001; 24(1): 24

 

 

Heide L, Biegert C, Wagner I, Rheumatische Erkrankungen, in: Angewandte Arzneimitteltherapie, 2001, Hrsg.: Schneemann H, Young LY, Koda-Kimble MA; Springer Verlag, Berlin, S. 343-361

 

Frey OR, Vor Zahnsteinentfernung Antibiotikum?, Medizinische Monatsschrift für Pharmazeuten 2000; 23(11): 372

 

 

Probst W, Aktuelles Wundmanagement (Current wound management), Deutsche Apotheker Zeitung 2000; 140(23): 67-69

 

 

Frey OR, Maier L, Polyethylene vials of calcium gluconate reduce aluminium contamination of TPN, Annales of Pharmcotherapy 2000; 34 (6): 811-12

 

 

Probst W, Vasel-Biergans A, Lokale Behandlung chronischer Wunden, Pharmazeutische Zeitung, 2000; 145 (46): 3907-20

 

 

Frey OR, Scheidt P, Irtel von Brenndorff AI, Nebenwirkungen durch Doxepin bei einem gestillten Neugeborenen, Krankenhauspharmazie 2000; 21 (5): 248

 

Frey OR, Baumann B, Maier L, Pecar A, Wagner R, PÄD-I.V. – Sichere Anwendung von intravenösen Arzneimitteln bei Kindern, 1. Auflage 2000 

 

  

Frey OR, Scheidt P, Von Brenndorff AI, Lugo SI, Kaiser J-M, Adverse effects in a newborn infant breast-fed by a mother treated with doxepin, Annals of Pharmacotherapy 1999; 33(6): 690-693

OBJECTIVE: To report adverse effects in a newborn infant whose mother had been treated with doxepin during pregnancy and while breast-feeding. CASE SUMMARY: The nine-day-old white boy was admitted because of poor sucking and swallowing, with muscle hypotonia and vomiting. He was drowsy and had lost 150 g. At the time of admission, he was breast-fed by his mother who was being treated with doxepin 35 mg/d. Samples of plasma and breast milk were taken and analyzed by HPLC and fluorescence polarization immunoassay. The amount of doxepin and N-desmethyldoxepin (DDP) ingested via breast-feeding was approximately 10-20 mug/kg/d (i.e., only 2.5% of the weight-adjusted dose of the mother). Doxepin was detectable in small amounts in the infant's plasma (10 mug/L); DDP was below the lower limit of detection of 10 mug/L. All adverse effects subsided within 48 hours after breast-feeding was stopped. DISCUSSION: Despite the small doses of doxepin and its active metabolite ingested by breast-fed babies, there is a risk of accumulation and resultant adverse effects. In newborns, the metabolic activity is considerably decreased and may be further reduced by hyperbilirubinemia. CONCLUSIONS: Available data suggest that women treated with doxepin should breast-feed their infants with great caution, if at all, although much larger databases are needed to confirm this. 

 

 

Frey OR, Probst W, Pharmakokinetik in der täglichen Praxis – Eine Einführung mit Übungen (Pharmacokinetics in the daily practice - An introduction with illustrations) PZ Prisma 1999;  6(1): 5-21

Download

 

 

Probst W, Arzneimitteltherapie bei Patienten mit Ernährungssonde – Beitrag des Apothekers  (Role pharmacist in medicating tube-fed patients), Krankenhauspharmazie 1999; 20(1): 17-21

Abstract: The role of the hospital pharmacist in improving drug therapy in tube fed patients is outlined. Regarding the choice of the drug various pharmacodynamic, pharmacokinetic and technological considerations are discussed: drug dosage forms, tube types and position, crushing of solid dosage forms, drug-food interactions, patient's assessment. Moreover, the pharmacist can have a positive impact in educating nursing stuff on proper drug administration in patients receiving enteral nutrition. The article gives an overview on the current literature being useful for the pharmacist's consulting.

 

 

Stahlmann SA, Frey OR, Kovar K-A, Stabilitätsstudie zu Fosfomycin-Dinatrium (Fosfocin p.p. 5.0) in applikationsfertigen Perfusorspritzen (Stability study: Aqueous solution of of Fosfomycin-Disodium (Fosfocin(TM) p.i. 5.0) in infusion syringes, Krankenhauspharmazie 1998; 19(12): 553-557

Abstract: Fosfomycin-Disodium is licensed for the antibiotic treatment of premature neonates. The preparation of ready-for-use infusions under aseptic conditions in  the hospital pharmacy is advisable, since suitable pack sizes are not available.  The stability of two solutions at concentrations of 50 mg/ml and 50 mg/3 ml in water for injection were investigated. Each solution was stored for several hours at room temperature with and without exposure to light, 4 days under refrigeration (8 [degree]C) and one month in frozen state (-20 [degree]C). Solutions were observed for discoloration and development of precipitate or turbidity. Qualitative and quantitative analysis was performed using HPTLC-FTIR on-line coupling. This procedure allows separation of mixtures by thin layer chromatography and identification and quantification of the separated components by their IR spectra. Reproducibility and precision were confirmed in a working range from 80-120% (m/m).

 

 

Frey OR, Pecar A, Baumann B, Maier L, Wagner R, Umfrage 1998 – Dienstleistugen von Krankenhausapotheken für die Pädiatrie (National survey 1998 - Pediatric pharmacy services in Germany), Krankenhauspharmazie 1999; 20(1): 22-24

Objectives: To examine the hospital structure and the type and levels of pharmacy services provided for pediatric patients and to evaluate the need of providing workshops in this field. Methods: A survey was sent to 600 hospital pharmacies. The survey instrument contained 26 questions on hospital demographics, on pharmacy services offered to pediatric departments and on the need of further education in this field. Results: Of the 239 responses, 117 hospital pharmacies are related to a department of pediatrics. Of these 117 pharmacies 94% provide the preparation of extemporaneus drug formulations, 38% provide the preparation of total parenteral nutrition solutions, 35% provide the preparation of cytotoxic agents, 9% provide pharmacokinetic consultations and 9% participate in ward rounds. Strong interest exists in workshops on pediatric nutrition (77%), on preparation of i.v. admixtures (62%), on participation in ward rounds (60%), on therapeutic drug monitoring (44%) and on pediatric oncology (36%). Conclusions: Most German hospital pharmacies prepare extemporaneus drug formulations for pediatric patients. Other services, especially pharmacokinetic consultation or participation in ward rounds are still rarely provided by German pharmacists. Based on data obtained in this study the working group on pediatrics of the German Association of Hospital Pharmacists (ADKA) will organize workshops in the requested fields, to support pharmacists in expanding these services.

 

 

Frey OR, Von Brenndorff AI, Probst W, Comparison of phenytoin serum concentrations in premature neonates following intravenous and oral administration, Annals of Pharmacotherapy 1998; 32(3): 300-303

Abstract: OBJECTIVE: To compare the serum concentrations attained following intravenous and oral administration of phenytoin in premature neonates. DESIGN: A prospective, uncontrolled study was conducted over 6 years. Phenhydan concentrate for infusion (Desitin, Hamburg, Germany) was used for intravenous infusion, and Epanutin suspension (Parke-Davis, Freiburg, Germany) was used for oral therapy. Blood samples were analyzed by using a fluorescence polarization immunoassay analyzer TDx model by Abbott Laboratories. SETTING: A university-affiliated district hospital. PARTICIPANTS: Twenty premature neonates who were administered intravenous and/or oral phenytoin between February 1991 and February 1997. MAIN OUTCOME MEASURES: Serum phenytoin concentrations on intravenous and oral phenytoin. RESULTS: Nine patients received intravenous (group A) and 15 patients received oral (group B) therapy. Mean +/- SD postnatal age (41 +/- 8.7 vs. 48 +/- 17 d; p = 0.03) and actual body weight (1.56 +/- 0.38 vs. 1.88 +/- 0.75 kg;  p = 0.02) were slightly higher in group B. There were no significant differences between the groups in mean +/- SD gestational age (26.1 +/- 1.37 vs. 26.9 +/-  3.30 wk), 5-minute Apgar score (8.7 +/- 1.11 vs. 7.7 +/- 2.26), daily dosage (8.1 +/- 3.86 vs. 8.1 +/- 4.21 mg/kg/d), and phenytoin serum concentration (8.7 +/- 7.36 vs. 9.6 +/- 5.83 mug/mL). CONCLUSIONS: Contrary to data in the current literature, reliable serum concentrations in premature neonates were achieved by oral administration of phenytoin suspension. Oral therapy offers a number of advantages and considerably reduces the cost of therapy. Due to substantial variations in phenytoin pharmacokinetics in neonates, close monitoring of serum concentrations is required. Further investigation is required to confirm these results, especially in neonates younger than 20 days' postnatal age and those receiving products other than Epanutin.

  

 

Probst W, Arzneimitteltherapie bei Patienten mit Ernährungssonde (Drug therapy in tube-fed patients), PZ Prisma 1997; 4(1): 31-41

 

 

Probst W, Der prä- und poststationäre Patient – Unser Kunde in der Krankenhausapotheke, Krankenhauspharmazie 1997; 18 (7): 331-32

 

 

Probst W, Der klinisch-pharmazeutische Fall – Lokale antibiotikatherapie bei chronischer Osteomyelitis (Clinical-pharmaceutical case report: Topical antibiotic therapy of chronic osteomyelitis), Krankenhauspharmazie 1996; 17(1): 7-9.

Abstract: A patient with an exacerbation of his chronic osteomyelitis develops a postoperative wound infection. The physician asks for an appropriate treatment with a topical quinolone. Taking the adequate bone penetration of different antibiotics into consideration, a systemic antibiotic therapy with Ofloxacin is recommended. In addition, the wound should be irrigated with a novel antiseptic caller Lavasept (polyhexanid). Monitoring parameters and the clinical outcome are discussed. Finally the contribution of the clinical pharmacist is emphasized.

 

 

Probst W, Therapeutisches Drug Monitoring: Workshop in Ulm, 30-31 August 1994.

Krankenhauspharmazie 1995, 16(2): 64-65

 

 

Fellhauer M, Probst W, Von Brenndorff AI, Ball M, Schweikardt B, Felis W, Therapeutisches Drug Monitoring von mit Gentamicin behandelten Frühgeborenen (Therapeutic drug monitoring for newborn babies treated with gentamicin), Krankenhauspharmazie 1994; 15(2):  58-61

Abstract: Gentamicin therapy in 118 newborn babies (33 prematures) was individualized´according to serum levels by the method of Sawchuk and Zaske. Peak levels in steady-state should be 6 mg/l, 7 mg/l or 8 mg/l, trough levels should be below 1.5 mg/l. In 59% of all patients the initial daily doses had to be changed by more than 10% in order to achieve these levels (in 78% of the babies with actual body weight below 2000 g, in 78% of the babies with gestational age below 37 weeks). The volume of distribution was 0.52 +/- 0.1 l/kg, serum half life was 5.8 +/- 2.0 hours and gentamicin clearance was 28.75 +/- 8.9 ml/min/1.73 m2 (mean +/- SD). These pharmacokinetic parameters showed significant differences (p < 0.05) between patients groups according to gestational age and body weight. It is concluded that therapeutic drug monitoring is recommended for babies with a gestational age below 37 weeks or a body weight below 2000 g.